Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses

To evaluate the role of V3-specific IgG antibodies (Abs) in the RV144 clinical HIV vaccine trial, which reduced HIV-1 infection by 31.2%, the anti-V3 Ab response was assessed. Vaccinees' V3 Abs were highly cross-reactive with cyclic V3 peptides (cV3s) from diverse virus subtypes. Sieve analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Zolla-Pazner, Susan, Edlefsen, Paul T., Rolland, Morgane, Kong, Xiang-Peng, deCamp, Allan, Gottardo, Raphael, Williams, Constance, Tovanabutra, Sodsai, Sharpe-Cohen, Sandra, Mullins, James I., deSouza, Mark S., Karasavvas, Nicos, Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Pitisuttihum, Punnee, Kaewkungwal, Jaranit, O'Connell, Robert J., Robb, Merlin L., Michael, Nelson L., Kim, Jerome H., Gilbert, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293639/
https://www.ncbi.nlm.nih.gov/pubmed/25599085
http://dx.doi.org/10.1016/j.ebiom.2014.10.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293639/
https://www.ncbi.nlm.nih.gov/pubmed/25599085
http://dx.doi.org/10.1016/j.ebiom.2014.10.022

Ejemplares similares